NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

痤瘡藥的全球市場

Acne Drugs

出版商 Global Industry Analysts, Inc. 商品編碼 992560
出版日期 內容資訊 英文 384 Pages
商品交期: 最快1-2個工作天內
價格
痤瘡藥的全球市場 Acne Drugs
出版日期: 2021年04月01日內容資訊: 英文 384 Pages
簡介

全球痤瘡藥的市場規模,預計在分析期間(2020年∼2027年)以4.1%的年複合成長率增長,從2020年的45億美元,到2027年達到59億美元。

本報告所分析的市場區隔之一的發炎性,在分析期間內預計將以4.4%的年複合成長率增長,達到32億美元。

本報告提供全球痤瘡藥市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Allergan Plc
  • AndroScience
  • Anterios
  • Aqua Pharmaceuticals
  • Bayer HealthCare
  • Cipher Pharmaceuticals
  • Galderma S.A.
  • GlaxoSmithKline Plc (Stiefel Laboratories, Inc.)
  • Johnson & Johnson
  • Mayne Pharma Group Limited
  • Mylan N.V.
  • Nestle S.A. (Galderma S.A.)
  • Oculus Innovative Sciences
  • Pfizer Inc.
  • Reckitt Benckiser
  • Skinvisible Pharmaceuticals
  • Stiefel
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
    • 競爭的市場佔有率:各市場區隔
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:42公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP21039

Abstract:

Global Acne Drugs Market to Reach $5.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Acne Drugs estimated at US$4.5 Billion in the year 2020, is projected to reach a revised size of US$5.9 Billion by 2027, growing at a CAGR of 4.1% over the analysis period 2020-2027. Inflammatory, one of the segments analyzed in the report, is projected to record a 4.4% CAGR and reach US$3.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Comedonal segment is readjusted to a revised 3.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 6.7% CAGR

The Acne Drugs market in the U.S. is estimated at US$1.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2027 trailing a CAGR of 6.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 3.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR.

Postsurgical / wound Segment to Record 3.6% CAGR

In the global Postsurgical / wound segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$367.3 Million in the year 2020 will reach a projected size of US$464.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$782.5 Million by the year 2027, while Latin America will expand at a 3.8% CAGR through the analysis period.

Select Competitors (Total 42 Featured) -

  • Allergan Plc
  • AndroScience
  • Anterios
  • Aqua Pharmaceuticals
  • Bayer HealthCare
  • Cipher Pharmaceuticals
  • Galderma S.A.
  • GlaxoSmithKline Plc (Stiefel Laboratories, Inc.)
  • Johnson & Johnson
  • Mayne Pharma Group Limited
  • Mylan N.V.
  • Nestle S.A. (Galderma S.A.)
  • Oculus Innovative Sciences
  • Pfizer Inc.
  • Reckitt Benckiser
  • Skinvisible Pharmaceuticals
  • Stiefel
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Acne Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Acne Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Acne Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Inflammatory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Comedonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Comedonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Comedonal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Postsurgical / wound by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Postsurgical / wound by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Postsurgical / wound by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Cystic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Cystic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Cystic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Retinoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Retinoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Retinoid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Antibiotic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Antibiotic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Antibiotic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Hormonal Agent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Hormonal Agent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Hormonal Agent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 40: USA Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: USA Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: USA 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 43: USA Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: USA Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: USA 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 46: USA Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: USA Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: USA 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 49: Canada Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Canada Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Canada 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 52: Canada Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Canada Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Canada 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 55: Canada Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Canada Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Canada 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 58: Japan Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Japan Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Japan 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 61: Japan Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Japan Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Japan 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 64: Japan Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Japan Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Japan 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 67: China Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: China Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: China 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 70: China Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: China Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: China 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 73: China Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: China Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: China 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 76: Europe Current & Future Analysis for Acne Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 77: Europe Historic Review for Acne Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Europe 15-Year Perspective for Acne Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 79: Europe Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Europe Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Europe 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 82: Europe Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Europe Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Europe 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 85: Europe Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Europe Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Europe 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 88: France Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: France Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: France 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 91: France Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: France Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: France 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 94: France Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: France Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: France 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 97: Germany Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Germany Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Germany 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 100: Germany Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Germany Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Germany 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 103: Germany Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Germany Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Germany 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 106: Italy Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Italy Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Italy 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 109: Italy Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Italy Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Italy 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 112: Italy Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Italy Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Italy 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 115: UK Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: UK Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: UK 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 118: UK Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: UK Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: UK 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 121: UK Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: UK Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: UK 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 124: Spain Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Spain Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: Spain 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 127: Spain Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Spain Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Spain 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 130: Spain Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Spain Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Spain 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 133: Russia Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Russia Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Russia 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 136: Russia Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Russia Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Russia 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 139: Russia Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Russia Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Russia 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 142: Rest of Europe Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Rest of Europe Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Rest of Europe 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 145: Rest of Europe Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Rest of Europe Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Rest of Europe 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 148: Rest of Europe Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Rest of Europe Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Rest of Europe 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 151: Asia-Pacific Current & Future Analysis for Acne Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 152: Asia-Pacific Historic Review for Acne Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Asia-Pacific 15-Year Perspective for Acne Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 154: Asia-Pacific Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Asia-Pacific Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: Asia-Pacific 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 157: Asia-Pacific Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Asia-Pacific Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Asia-Pacific 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 160: Asia-Pacific Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Asia-Pacific Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Asia-Pacific 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 163: Australia Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Australia Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Australia 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 166: Australia Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Australia Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Australia 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 169: Australia Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Australia Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Australia 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 172: India Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: India Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: India 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 175: India Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: India Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: India 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 178: India Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: India Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: India 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 181: South Korea Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: South Korea Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: South Korea 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 184: South Korea Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: South Korea Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: South Korea 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 187: South Korea Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: South Korea Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: South Korea 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 190: Rest of Asia-Pacific Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Rest of Asia-Pacific Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: Rest of Asia-Pacific 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 193: Rest of Asia-Pacific Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of Asia-Pacific Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: Rest of Asia-Pacific 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 196: Rest of Asia-Pacific Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Rest of Asia-Pacific Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: Rest of Asia-Pacific 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 199: Latin America Current & Future Analysis for Acne Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 200: Latin America Historic Review for Acne Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: Latin America 15-Year Perspective for Acne Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 202: Latin America Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Latin America Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: Latin America 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 205: Latin America Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Latin America Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 207: Latin America 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 208: Latin America Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Latin America Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 210: Latin America 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 211: Argentina Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Argentina Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 213: Argentina 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 214: Argentina Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Argentina Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 216: Argentina 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 217: Argentina Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Argentina Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 219: Argentina 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 220: Brazil Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Brazil Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 222: Brazil 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 223: Brazil Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Brazil Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 225: Brazil 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 226: Brazil Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 227: Brazil Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 228: Brazil 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 229: Mexico Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 230: Mexico Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 231: Mexico 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 232: Mexico Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 233: Mexico Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 234: Mexico 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 235: Mexico Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 236: Mexico Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 237: Mexico 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 238: Rest of Latin America Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 239: Rest of Latin America Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 240: Rest of Latin America 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 241: Rest of Latin America Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 242: Rest of Latin America Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 243: Rest of Latin America 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 244: Rest of Latin America Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 245: Rest of Latin America Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 246: Rest of Latin America 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 247: Middle East Current & Future Analysis for Acne Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 248: Middle East Historic Review for Acne Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 249: Middle East 15-Year Perspective for Acne Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 250: Middle East Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Middle East Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 252: Middle East 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 253: Middle East Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Middle East Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 255: Middle East 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 256: Middle East Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 257: Middle East Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 258: Middle East 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 259: Iran Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Iran Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 261: Iran 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 262: Iran Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 263: Iran Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 264: Iran 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 265: Iran Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Iran Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 267: Iran 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 268: Israel Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Israel Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 270: Israel 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 271: Israel Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Israel Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 273: Israel 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 274: Israel Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Israel Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 276: Israel 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 277: Saudi Arabia Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 278: Saudi Arabia Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 279: Saudi Arabia 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 280: Saudi Arabia Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 281: Saudi Arabia Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 282: Saudi Arabia 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 283: Saudi Arabia Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 284: Saudi Arabia Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 285: Saudi Arabia 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 286: UAE Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 287: UAE Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 288: UAE 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 289: UAE Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 290: UAE Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 291: UAE 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 292: UAE Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 293: UAE Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 294: UAE 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 295: Rest of Middle East Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Rest of Middle East Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 297: Rest of Middle East 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 298: Rest of Middle East Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Rest of Middle East Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 300: Rest of Middle East 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 301: Rest of Middle East Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Rest of Middle East Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 303: Rest of Middle East 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 304: Africa Current & Future Analysis for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 305: Africa Historic Review for Acne Drugs by Type - Inflammatory, Comedonal, Postsurgical / wound and Cystic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 306: Africa 15-Year Perspective for Acne Drugs by Type - Percentage Breakdown of Value Sales for Inflammatory, Comedonal, Postsurgical / wound and Cystic for the Years 2012, 2020 & 2027
    • TABLE 307: Africa Current & Future Analysis for Acne Drugs by Mode of Administration - Topical, Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 308: Africa Historic Review for Acne Drugs by Mode of Administration - Topical, Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 309: Africa 15-Year Perspective for Acne Drugs by Mode of Administration - Percentage Breakdown of Value Sales for Topical, Injectable and Oral for the Years 2012, 2020 & 2027
    • TABLE 310: Africa Current & Future Analysis for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 311: Africa Historic Review for Acne Drugs by Therapeutic Class - Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 312: Africa 15-Year Perspective for Acne Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Retinoid, Antibiotic, Hormonal Agent, Combination and Other Therapeutic Classes for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 42